Home Biosimilar Antibodies Immunology & Inflammation Immunology & Inflammation related Sabatolimab (anti-TIM-3)
For research use only. Not for use in humans.

Sabatolimab (anti-TIM-3)

Synonyms: HAVcr-2， CD366

Sabatolimab (anti-TIM-3) (MBG453, NVP-MBG453) is a high-affinity, humanized IgG4 antibody targeting TIM-3 on the surface of T-cells.

Sabatolimab (anti-TIM-3)

Click to purchase the isotype control of Sabatolimab (anti-TIM-3)

3 Citations

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: Purity: 99.44% Protein concentration: 6.3mg/ml Endotoxin Level: ＜1EU/mg
99.44

Specificity

Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description

Sabatolimab (anti-TIM-3) (MBG453, NVP-MBG453) is a high-affinity, humanized IgG4 antibody targeting TIM-3 on the surface of T-cells.
References

Product Details

CAS No. 2252262-24-9
Molecular Weight 145 KD
Isotype Human IgG4, κ
Application Sabatolimab (anti-TIM-3)
Source CHO cells
Purification Protein G
Sterility 0.2 μM filtered
Formulation PBS Buffer, PH 7.4
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05367401 WITHDRAWN Drug: Sabatolimab|Drug: Magrolimab|Drug: Azacitidine Myelodysplastic Syndromes; Acute Myeloid Leukemia Novartis Pharmaceuticals 2024-12-20 PHASE1; PHASE2
NCT05201066 ACTIVE_NOT_RECRUITING Drug: decitabine|Drug: spartalizumab|Drug: sabatolimab|Drug: Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic Novartis Pharmaceuticals 2023-02-28 PHASE2
NCT02817633 ACTIVE_NOT_RECRUITING Drug: TSR-022|Drug: Nivolumab|Drug: TSR-042|Drug: TSR-033|Dr Neoplasms Tesaro, Inc. 2016-07-08 PHASE1
NCT06056895 ACTIVE_NOT_RECRUITING Drug: Tuparstobart|Drug: Verzistobart Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8; Clinical Stage IV Merkel Cell Carcinoma AJCC v8; Merkel Cell Carcinoma University of Washington 2023-11-08 PHASE2
NCT06608940 WITHDRAWN Drug: BC3402|Drug: Durvalumab|Drug: Tremelimumab Hepato Cellular Carcinoma (HCC) Case Comprehensive Cancer Center 2025-11 PHASE1; PHASE2
NCT05357651 RECRUITING Drug: LB1410 Solid Tumor; Lymphoma L & L Bio Co., Ltd., Ningbo, China 2022-08-12 PHASE1

(data from https://clinicaltrials.gov, updated on 2024-04-11)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.